|
|
| 
 |
|
KEYNOTE SPEAKERS:
Carolyn M. Clancy, MD
Director, Agency for
Healthcare Research and Quality
USA
Carolyn
M. Clancy, M.D., was appointed Director of the Agency for Healthcare Research
and Quality (AHRQ) on February 5, 2003, and reappointed on October 9, 2009.
Prior to her appointment, Dr. Clancy was Director of AHRQ's Center for Outcomes
and Effectiveness Research.
Dr.
Clancy, a general internist and health services researcher, is a graduate of
Boston College and the University of Massachusetts Medical School. Following
clinical training in internal medicine, Dr. Clancy was a Henry J. Kaiser Family
Foundation Fellow at the University of Pennsylvania. Before joining AHRQ in
1990, she was also an assistant professor in the Department of Internal
Medicine at the Medical College of Virginia. Dr.
Clancy holds an academic appointment at the George Washington University School
of Medicine (Clinical Associate Professor, Department of Medicine) and serves
as Senior Associate Editor for the journal Health Services Research. She serves on multiple
editorial boards, including Annals of Internal Medicine, Annals of
Family Medicine, American Journal of Medical Quality, and Medical Care
Research and Review.
Dr.
Clancy is a member of the Institute of Medicine and was elected a Master of the
American College of Physicians in 2004. In 2009, she was awarded the William B.
Graham Prize for Health Services Research. Dr.
Clancy's major research interests include improving health care quality and
patient safety and reducing disparities in care associated with patients' race,
ethnicity, gender, income, and education. As Director of AHRQ, she launched the
first annual report to Congress on health care disparities and health care
quality.
 Danica Marinac-Dabic, MD, PhD
Director, Division of Epidemiology
U.S. Food and Drug Administration
Danica
Marinac-Dabic, MD, PhD is a Director of the Division of Epidemiology at the
Center for Devices and Radiological Health, Food and Drug Administration. She
is a physician and epidemiologist with the background in obstetrics, gynecology
and perinatal epidemiology. Dr. Marinac-Dabic leads three postmarket programs
at CDRH: (1) Post-Approval Studies Program, that encompasses the design,
review, monitoring and oversight of the post-approval studies mandated as a
condition of approval; (2) Postmarket Surveillance Studies Program, in charge
of postmarket studies mandated under Section 522 of the Act; and (3)
Epidemiologic Research Program, designed to augment medical device regulatory
research infrastructure and conduct independent epidemiologic research studies
to ensure CDRH science-based regulatory decision making. Dr. Marinac-Dabic
serves as a Chair of the CDRH Epidemiologic Research Council, and the Member of
the FDA Research Quality Assurance Board. Dr. Marinac-Dabic earned her M.D.,
Master of Science Degree in Human Reproduction and Ph.D. in Epidemiology from
the University of Belgrade Medical School, Belgrade, Yugoslavia. Dr.
Marinac-Dabic is the author of several book chapters, manuscripts and
presentations on various topics in the field of medical device epidemiology and
surveillance.
 Robert s.
Epstein, M.D., M.S.
President, United BioSource Corporation
Chief Clinical Research & Development Officer, Medco
In his current role, Dr. Robert
Epstein is responsible for the strategic direction of all United BioSource’s
business operations. In addition, Dr. Epstein oversees all of Medco’s research
initiatives in personalized medicine, drug safety, health economics, outcomes,
and comparative effectiveness conducted by researchers worldwide. Prior to his
current role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where
he led formulary development, clinical guideline development, drug information
services, personalized medicine programs, and client analytics and reporting.
Dr. Epstein is an epidemiologist and
worked in public health and academia before joining the private sector. He is
the former President of the International Society of Pharmacoeconomics and
Outcomes Research (ISPOR), and has served on the Board of Directors of the Drug
Information Association (DIA). In 2008, he was elected to the CDC EGAPP Stakeholder
Committee and the AHRQ CERT Steering Committee. He has published more than 50
peer-reviewed medical articles and book chapters, and serves as a reviewer for
several influential medical journals.
 Marc Berger, MD
Executive
vice president and Senior Scientist
OPTUM Insight, Inc, USA
A native of New York, he
has held senior positions in the pharmaceutical industry including Vice President,
Outcomes Research and Management at Merck & Co., Inc. from 2002 – 2007, and
Vice President, Global Health Outcomes, at Eli Lilly and Company from 2007 - 2011.
He obtained an M.D. degree from Johns Hopkins University School of
Medicine and has held adjunct appointments as Senior Fellow at the Leonard
Davis Institute at the Wharton School of the University of Pennsylvania and
Professor in the Department of Health Policy and Administration at the
University of North Carolina at Chapel Hill School of Public Health. He has served on the Medicare Evidence
Development & Coverage Advisory Committee (MedCAC) for the Center for
Medicare & Medicaid Services (CMS), the board of the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR), the steering committee for
the Agency for Health Care Research and Quality (AHRQ) Centers for Research and
Education on Therapeutics (CERTs), and the board of the Health Industry Forum
of the Heller School for Social Policy and Management at Brandeis University. Currently,
he is a member of the editorial advisory board of Value in Health, the advisory council for North America (ACNA) of
the Drug Information Association (DIA) and the Green Park Collaborative on
HTA/Payer Methods Guidance coordinated by the Center for Medical Technology
Policy (CMTP). He also currently serves as co-chair the ISPOR Taskforce on
Prospective Observational Studies for Comparative Effectiveness Research and as
chair of the AMCP/NPC/ISPOR Comparative Effectiveness Collaborative
IntiativeTaskforce for the Interpreting Prospective Observational Studies for
Health Care Decisions. Marc has published widely in peer-reviewed journals in
health services research, outcomes research, health economics, and health
policy.
Michael Laurer, MD
Director,
Division of Cardiovascular Sciences
National Heart, Lung, and Blood
Institute (NHLBI)
National Institute of Health (NIH), USA
In his current position, Dr. Lauer provides
leadership for the Institute's national program for research on the causes,
prevention, and treatment of cardiovascular (basic, clinical, population, and
health sciences) diseases. Dr. Lauer joined the NHLBI in July 2007.
Dr. Lauer’s primary research interests include
cardiovascular clinical epidemiology and comparative effectiveness, with a
focus on diagnostic testing. He also has a strong background in leadership of
the cardiovascular community and longstanding interests in medical editing—for
seven years he was a contributing editor for Journal of the American Medical
Association (JAMA) — and human subjects protection.
Prior to joining the NHLBI, Dr. Lauer served as the director of the Cleveland
Clinic Foundation Exercise Laboratory and vice chair of the clinic's
Institutional Review Board. He also
served as co-director of the Coronary Intensive Care Unit and director of
clinical research in the clinic's department of cardiology.
Dr. Lauer earned his Bachelor of Science degree
in biology, summa cum laude, from Rensselaer Polytechnic Institute in 1983 and
his Doctor of Medicine, magna cum laude, from Albany Medical College in 1985.
Following internal medical training at the Massachusetts General Hospital,
Harvard Medical School, he completed a clinical fellowship in cardiology at the
Boston Beth Israel Hospital, Harvard Medical School. His further training in
epidemiology included a research fellowship at the NHLBI’s Framingham Heart
Study, Boston University; the program in clinical effectiveness, Harvard School
of Public Health, Harvard University; and the Program for Physician Educators,
Harvard Macy Institute. 
David P. Recker, MD, FACR, FACP,
Senior Vice President Clinical Science,
Takeda Global Research & Development Center, Inc.
Dr. Recker oversees and directs global clinical research for pharmacologic agents in a variety of therapeutic areas. He joined the Takeda team in 2002. Dr. Recker has approximately 20 years of experience in pharmaceutical development. He has held prominent posts at Searle, IBEX Technologies, Corp., and Boots Pharmaceuticals having developed many pharmaceuticals in a variety of therapeutic areas.
Before joining the pharmaceutical industry, Dr. Recker spent time advising members of the Labor, Health and Human Services Subcommittee of the U. S. House Appropriations Committee on matters related to programs administered in the Department of Health and Human Services (HHS). Prior to that position, he was a Congressional fellow for the United States Congress Office of Technology Assessment where he helped formulate policy on various national health issues.
Art Sedrakyan, MD, PhD
Associate Professor
Director, Comparative Effectiveness Program Weill Cornell Medical College
Dr. Art Sedrakyan is an associate
professor at Weill Cornell Medical College and Director of Comparative Research
Program at HSS amd NYP. He is also an IPA senior adviser at the Food and Drug
Administration (FDA) and had appointments as senior service officer/senior
adviser at the FDA and Agency for Healthcare Research and Quality (AHRQ) from
2005 to 2009. He was a lead adviser on interventions (including surgery),
implantable devices and cardiovascular content area. He initiated the Effective
Healthcare CV Consortium and supervised two centers for Education and Research
in Therapeutics (CERTS); Cardiovascular CERT and orthopedic Device CERT. Dr.
Sedrakyan is serving on Medicare Evidence Development & Coverage
Advisory Committee (MEDCAC) from June 1, 2010. Prior to appointments at DHHS he
worked in the United Kingdom and has research and teaching experience from
Royal College of Surgeons (RCS) of England and London School of Hygiene
(LSHTM), London UK where he served as faculty, did health services research and
was Senior Adviser for National Collaborating Center for Acute Care (part of UK
National Institute of Clinical Excellence (NICE)).
Dr. Sedrakyan is a trained CT surgeon, a graduate of Johns Hopkins University
with Ph.D in Health Policy and Management and Yale Medical School with advanced
course work in Decision sciences, Clinical Epidemiology and Biostatistics.
President and Chief Medical Officer
VitalStrategic Research Institute
Danyi Zhang is the founder and the chief medical officer of VitalStrategic Research Institute (VSRI), a US and China based independent research organization with expertise in design and conduct evidence based clinical trials, comparative effectiveness research, health technology assessment and health information management. VSRI’s mission is to effectively define unmet medical needs and rigorously support initiatives that may improve global healthcare. Danyi has had a successful career in biopharmaceutical industry prior to founding VSRI. She has held leadership positions across drug development, medical affairs, and strategic planning, with increasing responsibilities. She most recently served a senior leadership at Bristol-Myers Squibb (BMS) as the medical director of global medical affairs and was responsible for developing medical strategy for the thrombosis and diabetes franchise, ensuring strategic integration of science and marketing. Prior to joining BMS, Danyi spent 5 years at Wyeth Pharmaceutical leading global strategic planning for cardiovascular and metabolic franchise and 4 years as a clinical research physician at Astra Merck. Dr. Zhang graduated from Shanghai First Medical College (now Fudan University), and received post-graduate training at Massachusetts Institute of Technology and Massachusetts General Hospital, Harvard Medical School. Her academic research focused on laser medicine and thrombotic diseases. In addition to her current role, she is the executive director of the Evidence Based Medical Research Center, School of Public Health, Fudan University, director of Coalition For Clinical Research in Cardiovascular and Metabolic Diseases, collaborated with CMDA, and a senior scholar at The School of Population Health, Thomas Jefferson University, in Philadelphia, PA.
PANEL LEADERS AND SPEAKERS:
Sheldon Kong, Ph.D.
Executive Director and Head of Global
Health Outcomes, Merck
Dr. Sheldon Kong leads a team of health economists,
epidemiologists, health service researchers, physicians, pharmacists and
statisticians to develop strategy and evidence to support the value proposition
of Merck pharmaceuticals and vaccines throughout the product lifecycle (from
early stage to patent expiry). Prior to joining Merck in 1997, he worked at G.
D. Searle & Co. as Associate Director, Pharmacoeconomics. He was Assistant
Professor of Pharmacy Administration at the University of Illinois at Chicago
(UIC) where he taught graduate level Pharmacoeconomics and Research Methods
before joining the industry and still holds appointment of Adjunct Professor.
He also holds appointment of Adjunct Professor at the Rutgers University Ernest
Mario School of Pharmacy.
Hong
Li, Ph.D., MPH
Group Director, Global Health Economics &
Outcomes Research
Bristol-Myers
Squibb Company
Working
out of USA, Dr. Li supports and coordinates HEOR strategies, activities and
projects of BMS products for various therapeutic areas, including
neurosciences, cardiovascular diseases, metabolic, immunology, oncology and
virology.
Dr.
Li is also an Adjunct Associate Professor of University of Cincinnati Medical
Center and Duke-NUS Graduate Medical School where he teaches
pharmaco-epidemiology and outcomes research to post graduate students.
Furthermore, Dr. Li is a founding member of the Asia Consortium of the
International Society of Pharmacoeconomics and Outcomes Research (ISPOR) which
is the international society of his professional field. Currently, he was the
chairman of the Advisory Committee of the Asian Consortium (2005-2007).
Dr.
Li holds a Ph.D. degree in Health Services Research/Epidemiology and a Master
of Public Health (MPH) degree in International Health Policy from School of
Public Health, University of North Carolina at Chapel Hill, USA. His major
academic research interests are healthcare project evaluation, international
healthcare policy evaluation, and applied epidemiology methodology in health
services research, such as drug utilization evaluation, evidence based
medicine, and clinical effectiveness research (or non-interventional research)
study design.
Zhi-Jie Zheng,MD， PhD
Dean,
School of Public Health,
University
Professor of Medicine and Public Health,
Shanghai Jiao Tong University
Dr. Zhi-Jie Zheng received his M.D. (1985) from Shanghai Medical University and M.A. in Bioethics (1988) from Department of Philosophy, Fudan University in Shanghai, China, and M.P.H. in health services research (1990) and Ph.D. in cardiovascular epidemiology (1994) from the University of North Carolina at Chapel Hill, USA. He completed his medical residency and fellowship training at Fudan University Medical Center, a Rockefeller Foundation sponsored International Clinical Epidemiology Network (INCLEN) Program at the University of North Carolina at Chapel Hill, and post-doctoral fellowship in epidemiology at the University of Minnesota in Minneapolis, USA. Dr. Zheng served as Lecturer at Shanghai Medical University (1987-1989), and Assistant Professor at the University of Kentucky Departments of Medicine (Cardiology) and Preventive Medicine (1997-1999).
From 1999-2006, Dr. Zheng was lead epidemiologist in the Division for Heart Disease and Stroke Prevention, US Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.Prior to joining Shanghai Jiao Tong University, Dr. Zheng was a Supervisory Medical Epidemiologist in the Division for the Application of Research Discoveries, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) in Bethesda, Maryland, USA. He led the NHLBI’s Cardiovascular Clinical Guidelines Development Program, and the NHLBI’s National Heart Attack Alert Program. He served as the Institute coordinator for global health and international programs at the NHLBI from 2006 to 2009.
Jianwei Xuan, Ph.D.
Senior
Director, Emerging Markets Business Unit, Pfizer
Prio
to his current role, Jianwei worked as Senior Director/Team Leader for multiple
therapeutic areas in global outcomes research group including Cancer,
Respiratory, Urology, Ophthalmology, Endocrinology, and Allergy within Pfizer
Inc. He managed multiple therapeutic area teams to provide product oriented strategic
outcomes research support to drive demand, support launch, and ensure access
and reimbursement for Pfizer products.
Prior
to joining Pfizer, Dr. Xuan worked in the outcomes research department in Glaxo
and he had progressive job responsibilities over time. His duties have included
directing and implementing health economic/outcomes research strategies and
tactical plans to substantiate the value of GSK products, providing health
economic input throughout product development life cycles, and assessing
marketing positioning.
Before
coming to USA, Jianwei worked in China’s Food and Drug Administration Bureau
for 6 years. His area of experience included IND and NDA review. Dr.
Jianwei Xuan received his undergraduate training from Shanghai Medical University;
M.S. Pharmaceutical Marketing, from University of North Carolina at Chapel
Hill, School of Pharmacy; and Ph.D. Health Economics/Health Services Research,
from School of Public Health, University of North Carolina at Chapel Hill. Dr.
Jianwei Xuan is also an adjunct professor at School of Public Health, Fudan
University, Shanghai, China and The college of Pharmacy, University of Florida;
USA.
Prof Shanlian Hu
School of Public Health, Health Economics
Director, Health Technology Management Training Cener
Fudan University
复旦大学公共卫生学院卫生经济学教授，博士生导师。卫生管理培训中心主任，复旦大学药物经济学评价与研究中心主任。现任上海市卫生发展研究中心主任。
目前担任的社会兼职工作有国务院深化医药卫生体制改革专家咨询委员会第一届委员、卫生部深化医药卫生体制改革专家委员会委员，卫生部卫生政策与管理专家咨询委员会委员，人力资源与保障部专家咨询委员会委员，卫生部社区卫生服务重点联系城市专家咨询委员会委员，上海市卫生改革与发展专家咨询委员会委员。上海市卫生局决策咨询专家委员会委员。中国医疗保险研究会常务理事。曾先后应邀为第二军医大学、西安医科大学、大连医学院、浙江大学及江苏东南大学的兼职教授。曾任世界卫生组织西太平洋区卫生系统研究委员会委员，世界卫生组织卫生政策与系统研究联盟委员。现为世界卫生组织基本药物咨询专家、国际药物经济学与结果研究协会亚洲分会离任主席。
近年来参与的研究项目有卫生部、国家发展与改革委员会、上海市卫生局、上海市食品药品监督管理局、联合国儿童基金会、世界银行、世界卫生组织及美国墨克国际基金会及多家外资或合资医药公司企业等组织资助的研究课题。近年来主要工作方向有卫生筹资、医药卫生体制改革、新型农村合作医疗制度研究，城市社区卫生服务、公共卫生服务均等化、医疗保险费用支付方式的比较研究、药品价格，基本药品政策及药物经济学等。
 Adèle R. Weston, PhD
Vice President, Health Economics & Outcomes Asia Pacific， OptumInsight
J. Brendan Mullen, Senior Director,
PINNACLE Programs American College of Cardiology
Brendan Mullen is the Senior Director for a suite of scientific, quality improvement, and payment recognition programs centered on the nation’s largest ambulatory cardiovascular data registry. Established in 2007, the PINNACLE Registry assesses adherence to evidence-based guidelines for coronary artery disease, heart failure, hypertension, and atrial fibrillation and now contains over 2.1 million records submitted by nearly 1,000 cardiologists, primary care physicians, and nurse practitioners. In this role, he is responsible for shaping both the scientific and operational trajectory of the registry and its affiliated programs. Mr. Mullen joined the College as its Director of Strategic Planning in the fall of 2008. Prior to the ACC, he worked for nearly ten years as a consultant for the Advisory Board Company, a healthcare research and consulting firm largely focused on hospital and health system strategy and operations. He previously served at the Department of Commerce and the International Trade Administration.
Mr. Mullen graduated magna cum laude and Phil Beta Kappa from Georgetown University’s School of Foreign Service with a degree in international economic theory.
Ramita Tandon
Global Head of Late Phase Clinical Trials
PAREXEL International
Ms. Tandon’s experience as a leader in late-phase development includes providing biopharmaceutical companies with a broad range of capabilities to support their product launch and marketing plans. She has in-depth expertise in late phase clinical development, including peri-and post approval studies, patient registries, safety studies and expanded access programs, and outcomes research. Ms. Tandon is focused on providing biopharmaceutical companies with customized strategic and scientific solutions to move products from development to commercialization in a seamless and cost-effective manner.
With more than 15 years of experience in the clinical product development industry and having worked extensively in peri- and post-approval clinical research, Ms Tandon has made significant achievements in the management of global business operations and has overseen several global launches for various products, across a broad range of therapeutic areas
Wilbur Liu, MD.PhD
Assistant Director, Medical Affairs Department
Head of Medical Excellence Function and Biosurgery therapeutic area in Sanofi China Dr. Liu has an educational background includes M.D. and Ph.D. for gastroenterology and hepatology from 1997-2003, doctor in charge and postdoc. of pancreatology from 2003 to 2005. In 2005, Dr. Liu joined AstraZeneca China as a brand physician and senior brand physician for GI therapeutic area, taking care of medical affairs and global, regional & local clinical development work, which led to completion of China GERD epidemiology study (SILC study). In 2008, he joined Genzyme (Shanghai) Biopharmaceutical Service Co. Ltd. as a medical manager for orphan drug in LSDs area. In 2010, Dr. Liu joined Sanofi Medical Affairs as an assistant director for medical excellence, responsible for medical education, medical publication, statistician, medical information, epidemiology/HEOR(health economic and outcome research), and for biosurgery products after Genzyme company joined Sanofi group. Dr. Liu has published more than 30 scientific articles, abstracts, and posters.
Patrick G. Chassaigne
Director, Late Phase Solutions
Medidata Solutions, Inc. As Director of Late Phase Solutions, Patrick assists pharmaceutical, biotechnology
and medical device companies utilize electronic data capture technology (EDC) to address the challenges of post-approval studies. His interactions with sponsors and Contract Research Organizations have led to the adoption of EDC resulting in increased site satisfaction and retention, better access to real-time data for analysis and improved decision making.Prior to joining Medidata, Patrick founded Chassaigne & Associates, a management
consulting company with a focus on increasing operational efficiency in life sciences and technology organizations.In addition, Patrick held the position of Director of Life Sciences at Compaq Computer Corporation (now HP), where he helped define the overall strategy for the company’s life sciences group by identifying customer requirements for discovery, pre-clinical, clinical and sales and marketing segments.Patrick has presented at global industry events including CBI's Registries and Post Approval Congress and DIA’s events. He holds an M.S. in Chemistry from Rensselaer Polytechnic Institute, in Troy, NY, and an M.S. in Chemical Engineering from L’Ecole Nationale Superieure de Chimie, Toulouse, France.
Joe
Caputo, BSc (Hons)
HEOR Principal, Asia Pacific Region, IMS Consulting Group
Joe Caputo is HEOR Principal for Asia Pacific
Region at the IMS Consulting Group in Singapore, leveraging 20 years of experience
in the pharmaceutical sector to help clients address the challenges of global
reimbursement and market access throughout the drug development programme. He
has led numerous projects involving patient level data, HTA submissions, local
market access models, payer research and value dossiers. With a background that spans industry roles
in drug development, sales & marketing and UK & global health outcomes,
and consulting in health economics & outcomes research, Joe has
wide-ranging knowledge of the drug development process at both local and
international level, and a unique understanding of evidence gaps in light of
reimbursement and market access requirements. Joe holds a degree in Applied Statistics and
has completed post-graduate courses in Economic Evaluation and Health
Economics.
PRE-CONFERENCE WORKSHOP LEADERS AND SPEAKERS
 Siyan Zhan, M.D, Ph.D
Professor and Deputy Director
Department of Epidemiology and Bio-statistics
Peking University Health Science Center
Professor Zhan graduated from Beijing Medical University in 1986, now the Peking University Health Sciences Centre, and obtained postgraduate training in the Chinese University of Hong Kong. Her major is Epidemiology, especially pharmacoepidemiology. She is the Deputy Director, Dept. of Epidemiology and Biostatistics, School of Public Health, Peking University. Since 1997, Prof. Zhan has been involved in the research and teaching of Evidence-based medicine. She is the Deputy Director, Peking University Centre for Evidence-Based Medicine and Clinical Research. In addition, she is also the chairman, Chinese Medical Doctor Association Evidence-based Medicine Committee. In recent years, she edited-in chief the book entitled Evidence-based Medicine and Evidence-based Healthcare, translated the famous EBM textbook, Evidence-based Medicine: How to Practice and Teach EBM (the third edition) into Chinese. She has published several papers of systematic review and meta-analysis.
Professor Zhan Siyan has been doing researches on the pharmacoepidemiology and evidence based medicine for the past few years. As a principal investigator or key personnel, she has already taken charge of many research projects related to the national ‘9th five-year’, ‘10th five-year’, ‘11th five-year’ plan and the national natural science foundation of China (NSFC). As a principal investigator, she took in charge of one WHO research program from 2008 to 2009. Professor Zhan Siyan has won many prizes, including 1 second-prize of national scientific and technological progress Achievement Award in 2001, and the Heinz Berends Award in Seattle, US in 2000.
 Feng Chen, PhD
Professor of Biostatistics Department
Nsnjing Medical University, School of Public Health
南京医科大学生物统计学教授，博士生导师。现任中国卫生统计学会统计理论与方法专业委员会主任委员，江苏省卫生统计学会主任委员，国家药品审评专家。主要从事生物医学高维数据和临床试验评价的统计理论与方法。是我国“临床试验中的生物统计学指导原则”的主要起草人之一。主持过国家自然科学基金项目，负责973、863、国家九五、十五攻关项目、十一五、十二五支撑项目、国家自然科学基金重大项目等课题的统计设计和分析，承担30多项新药临床试验的统计设计和分析。发表和联合发表论文160多篇，教材和学术专著18部。
 William Crown, PhD
President HEOR and Late Phase Research
Life Sciences, OptumInsight
Dr. Crown is President of a cluster of businesses within OptumInsight Life Sciences formerly known as Innovus, a global leader in health care economics, outcomes, and late phase research. Dr. Crown came to OptumInsight after spending more than a decade at Thompson Reuters Medstat, where he was Vice President of Outcomes Research and Econometrics in the Research and Pharmaceutical division. From 1982-1995, Dr. Crown was a faculty member at the Florence Heller Graduate School, Brandeis University, where he taught graduate courses in statistics and conducted research on the economics of aging and long-term care policy. He was Director of Policy Studies in the Policy Center on Aging from 1989-95, and Faculty Chair of the Heller School from 1992-93. He received his doctorate degree in urban and regional studies from the Massachusetts Institute of Technology, and a master of arts in economics from Boston University. The author of two books and co-author of two others, Dr. Crown has published more than 100 peer-reviewed journal articles, book chapters, and other scholarly papers. Known for his early application of sample selection bias models in the pharmaceutical outcomes research literature, he is a frequent speaker on pharmaceutical economics and econometric methodology at professional meetings and conferences. In addition to his management role within OptumInsight Life Sciences, Dr. Crown is Chair of the OptumInsight Fellows Program and a UHG Innovation Champion. In these latter roles, he applies his expertise in statistical methodology to a wide variety of problems in health care--ranging from the design of comparative effectiveness research studies to the evaluation of disease management programs.
Jieling Chen, PhD
Senior Health Economist,
Merck Research Laboratories
Dr. Chen joined the Health Economic Statistics Department at Merck in 2005. Her primary role has been providing health economic support in the area of diabetes and pneumococcal disease. Her research interest includes economic modeling, discrete event simulation, and evidence synthesis. Prior to working at Merck, She worked at the Wyeth Pharmaceuticals as senior health outcomes scientist. Jieling received an M.S. and Ph.D. in Economics from the University of Connecticut.
 |
|
